ArticleTherapeutic advances in medical oncology2020

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Bin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.